Pulmonary Arterial Hypertension | A Pipeline Analysis Report 2018 by Technavio

Technavio has published a new report on the drug development pipeline for pulmonary arterial hypertension, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

LONDON--()--Technavio has announced their latest pipeline analysis report on the pulmonary arterial hypertension market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat pulmonary arterial hypertension.

This report by Technavio presents a detailed analysis of the pulmonary arterial hypertension market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Pulmonary arterial hypertension: Market overview

Pulmonary arterial hypertension is a specific type of pulmonary hypertension, which can occur due to scarred tissue in small pulmonary arteries due to which the arteries become narrow in diameter leading to high blood pressure in lungs.

According to a senior analyst at Technavio for research on cardiovascular and metabolic disorders, “The right side of the hearth has to pump blood harder owing to the scarred tissue. Increased pumping can lead the heart to overwork, which in turn, can cause heart failure.”

Pulmonary arterial hypertension segmentation

This market research report segments the pulmonary arterial hypertension market based on therapies employed that includes (monotherapy, combination therapy, and unknown), RoA (oral, IV, subcutaneous, inhalation, IV+ subcutaneous, transdermal, and unknown), therapeutic modalities (small molecules, biological, recombinant fusion protein, monoclonal antibody, and unknown), targets for drugs under development (ACE2, activin receptor type IIA, AT2R, bone morphogenetic protein, bone morphogenetic protein receptor, bone morphogenetic protein receptor type II, dopamine beta hydroxylase, dopamine-serotonin 5-HT, endothelial progenitor, endothelin-1 receptor, endothelin receptor, and others), drugs under development (pre-clinical, discovery, phase I, phase II, and phase III), and recruitment status (not yet recruiting, recruiting, active not recruiting, ongoing, completed, and unknown). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age
  • Recruitment volume

Key Companies

  • Type of players
  • Company Overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Release Summary

Technavio presents its latest pipeline analysis report on pulmonary arterial hypertension, including a detailed study of the pipeline molecules.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200